Douglas Forsyth
Douglas Forsyth's purchase track record
Douglas Forsyth has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/8/2026 | INBX | $287K | pending | pending | — |
| 8/22/2024 | INBX | $1.04M | +7.6% | -1.5% | +9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NCV trades at unusual discount to sister fund NCZ. A recent analysis highlights that NCV is trading at an unusually wide discount compared to its sister fund, NCZ. This divergence between the two Virtus convertible funds has drawn attention from market observers. The fund currently shows a high dividend yield of 9.72% and a low P/E ratio of 4.1, which may be factors in its current valuation relative to NCZ.
Transaction History
| INBX | ▲ Buy | Open Market | 2,500 | $287K | 9/8/2026 | View on chart |
| INBX | ▲ Buy | Open Market | 59,812 | $842K | 8/23/2024 | View on chart |
| INBX | ▲ Buy | Open Market | 15,188 | $196K | 8/22/2024 | View on chart |
| INBX | ▲ Buy | Grant | 149,564 | — | 5/29/2024 | View on chart |
| NCV | ▼ Sell | Open Market | 2,500 | $26K | 6/25/2014 | View on chart |
| NCV | ▼ Sell | Open Market | 2,500 | $26K | 6/25/2014 | View on chart |
| NCV | ▼ Sell | Open Market | 9,000 | $95K | 6/25/2014 | View on chart |
| NCV | ▼ Sell | Open Market | 1,000 | $11K | 6/25/2014 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.